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ABSTRACT
Background and Aims Most US states have passed medical marijuana laws (MMLs), with great variation in program
regulation impacting enrollment rates. We aimed to compare changes in rates of marijuana use, heavy use and cannabis
use disorder across age groups while accounting for whether states enacted medicalized (highly regulated) or
non-medical mml programs. Design Difference-in-differences estimates with time-varying state-level MML coded by pro-
gram type (medicalized versus non-medical). Multi-level linear regressionmodels adjusted for state-level random effects and
covariates as well as historical trends in use. Setting Nation-wide cross-sectional survey data from the US National Survey
of Drug Use and Health (NSDUH) restricted use data portal aggregated at the state level. Participants Participants com-
prised 2004–13NSDUH respondents (n~67500/year); age groups 12–17, 18–25 and 26+ years. States had implemented
eight medicalized and 15 non-medical MML programs. Measurements Primary outcome measures included (1) active
(past-month) marijuana use; (2) heavy use (> 300 days/year); and (3) cannabis use disorder diagnosis, based on DSM-
IV criteria. Covariates included program type, age group and state-level characteristics throughout the study period.
Findings Adults 26+ years of age living in states with non-medical MML programs increased past-month marijuana
use 1.46% (from 4.13 to 6.59%, P = 0.01), skewing towards greater heavy marijuana by 2.36% (from 14.94 to 17.30,
P = 0.09) after MMLs were enacted. However, no associated increase in the prevalence of cannabis use disorder was found
during the study period. Our findings do not show increases in prevalence of marijuana use among adults in states with
medicalizedMML programs. Additionally, there were no increases in adolescent or young adult marijuana outcomes follow-
ing MML passage, irrespective of program type. Conclusions Non-medical marijuana laws enacted in US states are asso-
ciatedwith increasedmarijuana use, but only among adults aged 26+ years. Researchers and policymakers should consider
program regulation and subgroup characteristics (i.e. demographics) when assessing for population level outcomes. Re-
searchers and policymakers should consider program regulation and subgroup characteristics (i.e. demographics) when
assessing for population level outcomes.
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INTRODUCTION
TheUnitedStateshas enteredaneweraofmarijuanacontrol
policy during the past two decades [1]. As of the November
2016 election, 28 states andDChad legalized the use ofmar-
ijuana for medical indications through the passage of medi-
cal marijuana laws (MMLs), either by voter initiative or
legislative action. Additionally, eight states and Washington
DC (all of which allow formedicalmarijuana) have now fully
legalized the recreational use of marijuana by adults aged
more than 21 years, with implementation first beginning
in Colorado in 2014. In addition to differing combinations
of these laws, states also vary tremendously in regulations
guiding theirMMLprograms and participant eligibility [1,2].
Studies that investigate the impact of MML on rates of
adolescent and adult marijuana use, heavy use and
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cannabis use disorder have produced mixed findings [3,4].
Thismay be due in part to imprecise categorization of states.
For instance, in a recent study,Williams et al. [5] found that
highly medicalized state MML programs (those requiring
use of cannabinoid products with state licensed
manufacturing, dispensing, testing and labeling under close
physician supervision) hadmuch lower rates of enrollment,
whereas states with non-medical MML programs (i.e.
loosely regulated with few restrictions) involved more than
99.4%of the approximately 1millionMML program partic-
ipants active nation-wide as of October, 2014 [5].
Although MML program regulations may impact the
volume and characteristics of participants, there is also a
probable time effect on the cumulative number of people
participating in a given state (i.e. increasing participation
over time). Because loosely regulated non-medical MML
programs were passed disproportionately early (and there-
fore have been operating the longest) it is more challenging
to separate out the impact of regulation versus time.
Additionally, it is now understoodwidely thatMML program
participation was largely suppressed until 2008–09, due to
early concerns about possible federal enforcement that
would jeopardize patients and providers [5]. As a result,
studies of MML programs would probably be more accurate
if adjusting for MML passage in relation to 2008. Finally,
depending upon MML program regulation and resultant
patient characteristics, it may be that some states experience
higher prevalence of cannabis use disorder among
marijuana users. Higher prevalence of cannabis use disorder
and related consequences would be of great concern, given
the rapidly expanding use of marijuana nation-wide [4].
To determine whether accounting for variation in pro-
gram regulation clarifies the potential impact of MMLs on
prevalences of active (past-month) marijuana use, heavy
use (> 300 days/year) and cannabis use disorder, we stud-
ied the 50 states during the period 2004–13 to assess
trends in National Survey on Drug Use and Health
(NSDUH) data over time with particular emphasis on age
groups. Our aims were to: (1) identify whether passage of
medicalized versus non-medical MML programs had a dif-
ferential impact on rates of marijuana use, heavy use or
cannabis use disorder and (2), according to age group
(adolescents aged 12–17, young adults aged 18–25 and
adults aged 26+) during our study period.
METHODS
Design
In this study, we used a difference-in-differences regression
to examine changes in prevalence of marijuana use, heavy
use and cannabis use disorder after enactment of medical-
ized and non-medical MML programs, with aggregate
state-level data. Supporting information, Table S1 shows
the classification of the 23 states with operating programs
by the end of 2014 according to whether they enacted
medicalized (n = 8) or non-medical (n = 15) programs.
Washington DC was excluded from all analyses.
Data
We used cross-sectional survey data from the National Sur-
vey of Drug Use and Health (NSDUH) restricted use data
portal from 2004 to 2013 to obtain prevalences of mari-
juana use outcomes at the state level by year. NSDUH pro-
vides estimates of drug and alcohol use prevalence, as well
as drug use patterns and use-related problems, in the gen-
eral US civilian population aged 12 and older [6]. A multi-
stage probability sampling design allows for computation
of prevalence estimates that are representative of states
and national populations. Design-based weights adjust for
non-response and post-stratify to the known total US popu-
lation aged 12 and older [7]. TheNSDUH design also allows
for computation of representative estimates for different
socio-demographic groups at the state level. Each year,
NSDUH surveys ~67500 individuals, with an oversample
of younger age groups (~17500 youth aged 12–17 years
and ~17500 young adults aged 18–25 years [7,8].
The reliability and validity of the NSDUH measures
have been documented previously [9–11]. Professional
field interviewers conduct interviews using computer-
assisted interviewing methods, allowing respondents
highly private and confidential means of responding to sen-
sitive questions, which putatively increases the level of
honest reporting regarding illegal drug use and other sen-
sitive behaviors [7]. Survey screening response rates
ranged from 84 to 91% and interview response rates
ranged from 72 to 77% during the 2004–13 period.
Measures
Primary exposure variables
Enactment of state-level MMLs was our primary exposure
of interest. This variable was characterized by (1) whether
states had enacted a MML in a specific year, as determined
through review of state policies by legal scholars, econo-
mists and policy analysts at RAND Corporation [12] and
(2) whether the enacted MML included a medicalized or
non-medical program as determined on a previous classifi-
cation by Williams et al. [5]. MMLs were categorized as a
five-level, time-varying variable with the following levels
(as indicated in Supporting information, Appendix S1):
(1) before period for states with medicalized programs
(before-med), (2) after period for states with medicalized
programs (after-med), (3) before period for states with
non-medical programs (before-non-med), (4) after period
for states with non-medical programs (after-non-med)
and (5) states never enacting MMLs before 2015 (no
MML states). Eight states passed MML and four
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implemented medicalized programs by 2015: Connecticut,
Delaware, Massachusetts and New Jersey. These states
were coded as ‘before-med’ for the years before the enact-
ment of the law and as ‘after-med’ for years after (see
Supporting information, Appendix S1). For example, be-
cause Delaware enacted its MML in 2011, this state was
coded as ‘before-med’ for years 2004–10 and as ‘after’ for
years 2011–13. Similarly, the 15 states implementing
MML with non-medical programs were coded as ‘before-
non-med’ and ‘after-non-med’ following the same proce-
dure. States that had not enacted MML by 2015 were
coded as ‘never’ for all years. This procedure built upon
prior methodology by our group using before–after com-
parisons for all 50 states [13,14].
Active marijuana use
Our primary outcome was prevalence of active (past-
month) marijuana use across time at the state level. We
used the imputation-revised variable provided by NSDUH.
Prevalences were calculated for each state and each year
from NSDUH individual data.
Frequency of marijuana use in the past year
NSDUH participants using marijuana in the past year
responded to the following question: ‘We want to know
how many days you’ve used marijuana or hashish during
the past 12 months. What would be the easiest way for
you to tell us how many days you’ve used it?’. Individuals
could choose from three options: (1) average number of days
per week, (2) average number of days per month or (3) total
number of days in the past 12 months. Individuals were
then asked about frequency of use according to their answer
to the previous question: e.g. ‘On howmany days in the past
12 months did you use marijuana or hashish?’. NSDUH
provides an imputation-revised variable aggregating re-
sponses to these previous questions. We dichotomized this
variable as having used marijuana < 300 days versus
> 300 days/year (‘heavy use’) in the past 12 months [15].
Cannabis use disorder
Participants were classified as having marijuana abuse or
dependence based on DSM-IV criteria [16]. We used the
NSDUH cannabis use disorder (abuse and/or dependence)
imputation-revised variable. Prevalences were calculated
for each state and year from NSDUH individual data.
State-level covariates
State-level control variables included the proportion of
each state’s population of male, white, aged 10–24 and
at least high school-educated individuals in the population
aged> 25 years, the state unemployment rate andmedian
household income. Census values from 2000 and 2010
were used for 2004–05 and 2006–13, respectively.
Statistical analyses
The prevalences of active marijuana use, heavy use and
cannabis use disorder were calculated using Taylor’s series
linearization estimation methods to account for the com-
plex survey design features of the NSDUH [17].
To examine whether states’ implementation of med-
icalized or non-medical MML programs was associated
with changes in marijuana outcomes, we used multi-
level linear regression models [18] with state-level
random intercepts to account for repeated measure-
ments within states over time and also adjusted for
state-level covariates. In addition, we used a piecewise
cubic spline [19], with a knot at 2008 to control for
the non-linearity of national trends in past-month
marijuana use; this allowed us to control for any
national trends that could have influenced the preva-
lence of marijuana use over time. Based on the NSDUH
complex survey design, age was included as a three-
level predictor for age groups of interest (12–17,
18–25, 26+ years) interacting with the five-level
MML variable to allow for differential effects of passage
of MML and type of program (i.e. medicalized or
non-medical) on marijuana use by age group.
The use of the five-level MML-type of program
variable in these models allowed us to compare the aver-
age prevalence of past-month marijuana use in the
before-MML period versus the after-MML period through-
out MML states specifically with medicalized programs,
while controlling for contemporaneous trends in states
that never enacted MML; similarly, we were able to
compare the average prevalence of marijuana use in the
before-MML versus after-MML periods throughout states
enacting non-medical programs.
RESULTS
Change in the prevalence of active marijuana use after the
enactment of MML
Models adjusted for national trends showed no significant
change in the prevalence of past-month marijuana use
among adolescents or young adults (those aged 18–25) af-
ter the enactment of MML, irrespective of whether MML
programs were medicalized or non-medical (see Table 1).
Significant increases in active marijuana use, from 4.13
to 6.59% (1.46 prevalence points; P = 0.01), were ob-
served among those aged 26+, but only in states passing
non-medical MML programs (see Fig. 1).
Change in the prevalence of heavy marijuana use after the
enactment of MML
There was a reduction in the prevalence of heavy
marijuana use among adolescent active users, from
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9.90 to 6.23% (P = 0.04), in medicalized states;
however, results showed no significant changes in states
with non-medical MML programs (see Table 1); nor
was there a significant change in the prevalence of
heavy marijuana use among users aged 18–25 after
the enactment of MML, irrespective of whether states
had medicalized or non-medical MML programs. Only
among those aged 26+ living in states with non-medical
MML programs was there an increase, from 14.94 to
17.30% (2.36% annually; P = 0.09) in the prevalence
of heavy marijuana use among active users after the en-
actment of MML; however, this finding was just shy of
significance (see Fig. 2).
Change in the prevalence of cannabis use disorder after the
enactment of MML
Our results did not show evidence of increased preva-
lence of cannabis use disorder (abuse and/or dependence
according to DSM-IV criteria) among adolescents or
adults after states enacted MML, irrespective of program
type (see Table 1). There was a slight reduction in prev-
alence of cannabis use disorder among young adults
(18–25 years), from 7.07 to 6.27% (0.80 prevalence
points; P = 0.01), after enactment in states with non-
medical MML programs (see Fig. 3).
Sensitivity analyses were conducted for key analyses.
For instance, treating each state as a fixed effect (i.e.
using dummy variables) rather than as a random effect
in our modeling strategy did not change our results.
Although we modeled time initially using a cubic form
with a spline in 2008 (given the change in the preva-
lence of marijuana use starting in 2008), we additionally
modeled time as a fixed effect with a dummy variable for
each year, which also did not impact upon our results.
DISCUSSION
Our findings show that increases in rates of marijuana use
following the passage of MML are restricted to adults aged
26+ in states implementing non-medical MML programs.
Further, the magnitude of MML program impact upon
rates of marijuana usemay be greatest among heavy users,
leading to an annual increase in near-daily users of 2.36%
(absolute percentage change); however, this trend should
be monitored over time.
Our findings are consistent with prior studies finding
increases in rates of marijuana use among adults (but not
Table 1 Before–after changes in marijuana outcomes by age and state MML program type.





(after versus before) 95% CI P-value
Change in prevalence of active (past-month) marijuana use by age group and state MML program type
Age 12–17, medicalized 7.85 7.56 0.28 1.70; 1.13 0.70
Age 12–17, non-medical 8.64 9.21 0.57 0.60; 1.74 0.34
Age 18–25, medicalized 20.88 21.27 0.74 1.07; 1.84 0.60
Age 18–25, non-medical 21.26 21.90 0.65 0.62; 1.91 0.32
Age 26+, medicalized 4.35 4.51 0.15 1.24; 1.55 0.83
Age 26+, non-medical 4.13 6.59 1.46 0.33; 2.58 0.01
Change in prevalence of heavy marijuana use (> 300 days/year) among users by age group and state MML program type
Age 12–17, medicalized: after to before 9.90 6.23 3.67 7.24;0.11 0.04
Age 12–17, non-medical: after to before 10.04 9.18 0.85 3.48; 1.78 0.53
Age 18–25, medicalized: after to before 17.23 16.86 0.38 4.12; 3.37 0.84
Age 18–25, non-medical: after to before 17.37 19.14 1.77 1.13; 4.68 0.23
Age 26+, medicalized: after to before 12.79 12.82 0.03 3.61; 3.68 0.99
Age 26+, non-medical: after to before 14.94 17.30 2.36 0.39; 5.11 0.09
Change in prevalence of cannabis use disorder by age group and state MML program type
Age 12–17, medicalized: after to before 3.51 3.17 0.34 1.09; 0.42 0.38
Age 12–17, non-medical: after to before 3.83 4.13 0.30 0.32; 0.92 0.34
Age 18–25, medicalized: after to before 6.21 6.04 0.18 0.94; 0.59 0.64
Age 18–25, non-medical: after to before 7.07 6.27 0.80 1.45;0.16 0.01
Age 26+, medicalized: after to before 0.64 0.66 0.02 0.66; 0.71 0.94
Age 26+, non-medical: after to before 0.81 0.95 0.14 0.37; 0.65 0.59
aAverage prevalence before the enactment of medical marijuana laws (MML) (eight medicalized MML states and five non-medical states had before MML data
available); baverage prevalence after the enactment of MML (four medicalized MML states and 15 non-medical states had after MML data available).
CI = confidence interval.
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adolescents) in states with MMLs. Wen and colleagues
found increases in marijuana use among individuals aged
more than 21 years of age in states with MMLs [3]. Mar-
tins and colleagues also found increases among adults
aged 26+ in states with MMLs compared to states without
MMLs [14]. Most recently, Hasin et al. 2017 [20] also
found increases among adults in states with MML but
did not account for variation across states in program reg-
ulation. Our results suggest that these increases may be
concentrated disproportionately in states with non-
medical MML programs. As a result, the diluted effect sizes
of MMLs on prevalence of marijuana use found in prior
studies may betray the greater increases specific to individ-
uals with access to loosely regulated programs with mini-
mal physician involvement in a subset of states that
implemented non-medical MML programs (n = 15 as of
2014). However, given that only four states enacted med-
icalized MML programs during our study period, we may
have been underpowered to detect significant changes in
these states.
There is concern that with the increase in prevalence of
marijuana use, especially heavy use, there will be a propor-
tionate increase in the percentage of the population meet-
ing diagnostic criteria for cannabis use disorder [4]. If this is
the case, states with non-medical programs may bear the
brunt of this increase, especially among adults aged more
than 25 years. However, the increase in heavy marijuana
use may, alternatively, reflect daily use for medical indica-
tions under the aegis of MMLs rather than recreational
purposes [14,21].
Figure 2 Trends in past-month marijuana use, heavy marijuana use (> 300 days/year) and marijuana use disorder among individuals aged
18–25 years. MML = medical marijuana law
Figure 3 Trends in past-month marijuana use, heavy marijuana use (> 300 days/year) and marijuana use disorder among individuals
aged > 26 years. MML = medical marijuana law
Figure 1 Trends in past-month marijuana use, heavy marijuana use (> 300 days/year) and marijuana use disorder among individuals aged
12–17 years. MML = medical marijuana law
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Although we found a slight significant reduction
(0.80 prevalence points, P = 0.01) in cannabis use disor-
der among young adults in states with non-medical pro-
grams, no other statistically significant changes were
found. It may be too early to detect trends across states re-
garding the prevalence of cannabis use disorder, as the time
lag between initiation of marijuana use, escalation of use
and meeting diagnostic criteria for cannabis use disorder
is often several years. As a result, downstream effects of
changes inmarijuana use prevalences may not be reflected
in currently available NSDUH data on cannabis use disor-
der rates and might be reflected only with analyses con-
ducted in future years with more data points. Given the
tremendous interest in the potential impact of MMLs on
population-level outcomes, such as rates of cannabis use
disorder, and given that several of these states first passed
laws almost 20 years ago, we thought it was prudent to as-
sess for potential increases in the rates of cannabis use dis-
order by age category. We believe our current (largely
negative) findings are relevant; however, we cannot rule
out impending increases in cannabis use disorder defini-
tively without further study.
There are several limitations to our study. Foremost,
given the trend among states to pass increasingly regulated
medical marijuana programs, the majority of highly medi-
calized programs were passed starting in 2009, limiting
sample size among the newer, medicalized programs
within our study period. Additionally, working with aggre-
gated data at state-level limits our ability to assess for sub-
group differences (i.e. race, sex, level of education, etc.) at
the individual person-level. Further studies are needed to
determine whether these findings are consistent across all
subgroups of adults and adolescents, as the impact of regu-
lation may affect individuals differentially based on gender,
race or socio-economic status, in addition to age. For in-
stance, our classification was based on a prior study by
Williams et al. that relied upon seven components
reflecting medicalization of program regulation. Further
studies may identify alternative components (such as den-
sity of dispensaries, approved indications for use, or out of
pocket costs), or combinations thereof, that have greater
associations with population level outcomes. Finally, al-
though we included several state-level covariates as ran-
dom and fixed effects that may have affected our findings,
there may be additional covariates impacting marijuana
outcomes for which we did not control (such as other
trends in substance use disorders or the burden of certain
medical conditions within a given state).
CONCLUSION
Given great increases in national trends of marijuana use
and heavy marijuana use among adults throughout much
of the country, there is growing concern that states have
been slow to address impending morbidity and social costs
among the millions of Americans now using marijuana le-
gally. Accounting for variation in state MML program reg-
ulations may help to guide prevention and treatment
efforts to populations (i.e. aged 26+) within states at
greater risk for unintentionally increasing rates of heavy
marijuana use and related problems. Our findings suggest
strongly that researchers should not treat all states with
MML uniformly. Rather, key aspects of regulation that are
lacking among non-medical programs, such as active phy-
sician oversight, sanctioning smoked whole plant mari-
juana and requiring participation in state-licensed
dispensaries and the use of state-licensed products should
be investigated further, as they may have a greater influ-
ence on individual morbidity and social costs than the
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Supporting Information
Additional Supporting Information may be found online in
the supporting information tab for this article.
Appendix S1 State MML Program Type and Change in
Prevalence of Marijuana Before and After Passage.
Table S1 State MML program type and change in preva-
lence of marijuana before and after passage.
MMLs: Marijuana Use & Cannabis Use Disorder 7
© 2017 Society for the Study of Addiction Addiction
